HPS Pharmacies prides itself on providing innovative and informative support to assist in the diverse range of issues health professionals face on a day-to-day basis, and to facilitate the distribution of this information for a variety of sectors within the healthcare industry.
HPS’ clinical articles are written by HPS Pharmacies’ experienced and knowledgeable staff and are peer-reviewed by specialist leaders in their field to ensure the accuracy of the information provided. The resourceful and diverse range of articles play an integral role in keeping all health professionals up-to-date with the happenings throughout the industry on a regular basis.
Monkeypox has been declared a Communicable Disease Incident of National Significance in Australia. As of 16 August 2022, 82 probable or confirmed cases of monkeypox have been reported to the National Notifiable Diseases Surveillance…
Read more
Background Anticholinergic burden is defined as the cumulative effect of taking multiple anticholinergic medications resulting in an increased risk of adverse effects. High, long-term cumulative exposure has been linked to an increased risk of…
Read more
The ubiquitous belief that a course of antibiotics should be taken until finished has its origins in the Nobel prize speech in 1945 by John Fleming when he advocated: “If you use penicillin, use…
Read more
Venous thromboembolism (VTE) may include a deep vein thrombosis (DVT) or a pulmonary embolism (PE). The incidence of VTEs in terminal phase palliative care patients is often difficult to determine, which may be because…
Read more
Although the oral route should be maintained for as long as possible in a palliative care setting, there are a variety of circumstances where commencing a continuous subcutaneous infusion (CSCI) may be beneficial. This…
Read more
HPS Pharmacies is delighted to share the following study overview written by Natansh Modi, a pharmacist at HPS Pharmacies St Andrew’s. The study, conducted by Natansh and her colleagues, looked at patient-reported outcomes in…
Read moreMonkeypox in Australia (Aug. 19 2022)
Anticholinergic Burden (Aug. 05 2022)
New Therapy for Cystic Fibrosis (Apr. 29 2022)
Seasonal Influenza Vaccination (Apr. 14 2022)
Paroxysmal Nocturnal Haemoglobinuria (Apr. 01 2022)
Aged Care and Chemical Restraint (Mar. 18 2022)
Molnupiravir for COVID-19 (Mar. 04 2022)
SGLT2 Inhibitors for Heart Failure (Feb. 18 2022)
COVID-19 Treatment Options (Feb. 04 2022)
What is Cancer Survivorship Care? (Jan. 21 2022)
Managing the Side Effects of Chemotherapy (Dec. 31 2021)
COVID-19 Vaccine Boosters (Dec. 17 2021)
Glucagon-like Peptide-1 Analogues (Dec. 03 2021)
Antimicrobial Awareness Week (Nov. 18 2021)
Restless Legs Syndrome (Nov. 05 2021)
Medication Interactions with Food (Oct. 21 2021)
Revised Delirium Clinical Care Standard (Oct. 08 2021)
Hepatitis B Reactivation (Sep. 23 2021)
Antimicrobial resistance: The need for stewardship (Sep. 08 2021)
Cannabis (Aug. 26 2021)
Melanoma – An Update in Treatment Strategies (Aug. 13 2021)
New Labelling Standard (Jul. 30 2021)
Prevention of Shingles (Jul. 16 2021)
Melatonin down scheduling: a brief update (Jul. 01 2021)
Topical treatment in psoriasis (Jun. 17 2021)
Progress of Cervical Cancer Elimination (Jun. 04 2021)
New Action Plan for Pain Management (May. 21 2021)
Thyroid Awareness Month (May. 06 2021)
Influenza Vaccines (Apr. 23 2021)
Treatment of Eosinophilic Oesophagitis (Apr. 09 2021)
Hospital-initiated Medication Reviews (Feb. 26 2021)
Boxed Warnings for Gabapentinoids (Feb. 10 2021)
COVID-19 Vaccines (Jan. 28 2021)
Updates to the Poisons Standard (Jan. 15 2021)
Active Ingredient Prescribing (Dec. 23 2020)
New Digital Mental Health Standards (Dec. 18 2020)
Approval of New Prescription Medications (Dec. 04 2020)
Antimicrobial Resistance (Nov. 20 2020)
Vaccines and Cold Chain (Nov. 06 2020)
Darolutamide (Nubeqa®) in Prostate Cancer (Oct. 22 2020)
Drugs in Sport (Oct. 09 2020)
Treatment of Infantile Haemangioma (Sep. 25 2020)
Abemaciclib for Breast Cancer (Sep. 11 2020)
Primary Cutaneous T-cell Lymphoma (Aug. 28 2020)
Gliflozins and Heart Failure (Aug. 12 2020)
Remdesivir – an emerging treatment for COVID-19 patients. (Jul. 31 2020)
Safe Injection Practices (Jul. 17 2020)
Diabetes and Insulin (Jul. 02 2020)
Hydroxychloroquine as triple therapy in COVID-19 patients (Jun. 16 2020)
Tocilizumab, COVID-19 and the cytokine storm (Jun. 03 2020)
Colchicine use in Acute Myocardial Infarction (May. 20 2020)
Changes to Opioid PBS Listings (May. 06 2020)
Coronavirus Disease (Apr. 22 2020)
Risk of Viral Transmission with Nebulised Medication Delivery (Apr. 09 2020)
Xerostomia (Feb. 27 2020)
Monoclonal Antibodies for Migraine (Feb. 13 2020)
Changes to Neural Connector Devices (Jan. 30 2020)
Venetoclax (Jan. 16 2020)
Biosimilars in Oncology (Jan. 03 2020)
Prescription Opioid Changes (Nov. 22 2019)
Diabetes Medications in the Peri-Operative Period (Nov. 08 2019)
Lamotrigine Dose Escalation (Oct. 25 2019)
Wilson Disease (Oct. 11 2019)
Parkinson’s Disease and Hospitalisation (Sep. 27 2019)
Understanding Clinical Trials (Sep. 13 2019)
Short-Course Oxycodone Packs (Aug. 30 2019)
Tafenoquine: A Novel Anti-Malarial (Aug. 16 2019)
Medicinal Marijuana? (Aug. 02 2019)
Primary Prevention: a Low-Dose Aspirin Story (Jul. 19 2019)
Hand-Foot Syndrome (Jul. 08 2019)
Low Dose Methotrexate for Rheumatoid Arthritis (Jun. 21 2019)
Introduction to the storage of medications in a private hospital setting (Jun. 07 2019)
Lactulose for Hepatic Encephalopathy (May. 24 2019)
Proton Pump Inhibitor Restrictions (May. 10 2019)
Prevention of Recurrent Clostridium difficile Infection (Apr. 25 2019)
Updates to the Australian Asthma Handbook (Apr. 12 2019)
Heparins (Mar. 29 2019)
Safety and Quality Standards for Mental Health (Mar. 15 2019)
Potentially Harmful Medication Use in the Elderly (Mar. 01 2019)
Animal-Assisted Therapy for Dementia (Feb. 15 2019)
Augmented Renal Clearance (Feb. 01 2019)
Biofilms (Jan. 18 2019)
Medications and Sun Exposure (Jan. 04 2019)
